Sanotize is recruiting for a COVID trial in the provinces of Quebec and Ontario.   

SaNOtize has been evaluating nitric oxide (NO), a naturally occurring nanomolecule in the body, as a first-in-class nitrosylite drug with potential use as a topical antimicrobial agent to treat a wide variety of diseases.

SaNOtize has an issued patent for its Nitric Oxide Releasing Solution (NORSTM).

The company’s key objective is to provide a first-line non-antibiotic antimicrobial for use against bacterium, viruses and fungi. With this approach, antibiotic therapies may be reserved for more severe infections, used less frequently, and ultimately slow the development of AMR.

In addition to its ability to treat a broad spectrum of infectious pathogens, NORSTM delivery is practical and convenient. The development of a proprietary liquid formulation to generate NO as an antimicrobial and immunomodulatory agent means that high-pressure cylinders of gNO are not required for delivery.

Patented NORSTM Technology

  • Stable Storage
  • Low manufacturing cost and scalable
  • Established safety profile
  • Can be delivered topically as liquid/gel
logged in